Skip to main content Accessibility help

Economic impact of recurrent respiratory papillomas in a UK adult population

  • A Harrison (a1), J Montgomery (a2) and F B Macgregor (a3)



To calculate the financial burden of recurrent respiratory papilloma. This study is UK-based, where up until now no financial estimates have been calculated for this group of patients.


Recurrent respiratory papilloma is caused by the human papilloma virus (subtypes 6 and 11). The burden for the patient and the healthcare system is significant given the recurrent nature of the disease.


Data were collected, using a questionnaire completed during routine clinical follow up, from a single centre managing recurrent respiratory papilloma in Glasgow, Scotland. Cost information was sourced from the Scottish Government's Information Services Division.


Fourteen patients with active recurrent respiratory papilloma between 2013 and 2014 were identified. The direct measurable cost to NHS Greater Glasgow and Clyde amounted to £107 478.


Recurrent respiratory papilloma is a benign condition, but the financial implications of diagnosis are significant. Recurrent respiratory papilloma has a natural history of relapse and remission, and patients may require healthcare input over a period of several years.


Corresponding author

Address for correspondence: Miss Anna Harrison, Department of Otolaryngology, North Manchester General Hospital, Delaunays Road, Manchester M8 5RB, UK Fax: 0161 778 3646 E-mail:


Hide All
1Goon, P, Sonnex, C, Jani, P, Stanley, M, Sudhoff, H.Recurrent respiratory papillomatosis: an overview of current thinking and treatment. Eur Arch Otolaryngol 2008;265:147–51
2Larson, DA, Derkay, CS.Epidemiology of recurrent respiratory papillomatosis. APMIS 2010;118:450–4
3Hill, DS, Akhtar, S, Corroll, A, Croft, CB.Quality of life issues in recurrent respiratory papillomatosis. Clin Otolaryngol Allied Sci 2000;25:153–60
4Carifi, M, Napolitano, D, Morandi, M, Dall'Olio, D.Recurrent respiratory papillomatosis: current and future perspectives. Ther Clin Risk Manag 2015;11:731–8
5Loizou, C, Laurell, G, Lindquist, D, Olofsson, K.Voice and quality of life in patients with recurrent respiratory papillomatosis in a northern Sweden cohort. Acta Otolaryngol 2014;134:401–6
6Derkay, CS, Volsky, PG, Rosen, CA, Pransky, SM, McMurray, JS, Chadha, NK.Current use of intralesional cidofovir for recurrent respiratory papillomatosis. Laryngoscope 2013;123:705–12
7Healy, GB, Gelber, RD, Trowbridge, AL, Grundfast, KM, Ruben, RJ, Price, KN.Treatment of recurrent respiratory papillomatosis with human leukocyte interferon. Results of a multicenter randomized clinical trial. N Engl J Med 1988;319:401–7
8Leventhal, BG, Kashima, HK, Mounts, P, Thurmond, L, Chapman, S, Buckley, S et al. Long-term response of recurrent respiratory papillomatosis to treatment with lymphoblastoid interferon alfa-N1. Papilloma Study Group. N Engl J Med 1991;325:613–17
9Gerein, V, Rastorguev, E, Gerein, J, Jecker, P, Pfister, H.Use of interferon-alpha in recurrent respiratory papillomatosis: 20-year follow-up. Ann Otol Rhinol Laryngol 2005;114:463–71
10Endres, DR, Bauman, NM, Burke, D, Smith, RJ.Acyclovir in the treatment of recurrent respiratory papillomatosis. A pilot study. Ann Otol Rhinol Laryngol 1994;103:301–5
11Lippman, SM, Donovan, DT, Frankenthaler, RA, Weber, RS, Earley, CL, Hong, WK et al. 13-Cis-retinoic acid plus interferon-alpha 2a in recurrent respiratory papillomatosis. J Natl Cancer Inst 1994;86:859–61
12Lu, B, Kumar, A, Castellsaqué, X, Giuliano, AR.Efficacy and safety of prophylactic vaccines against cervical HPV infection and diseases among women: a systematic review and meta-analysis. BMC Infect Dis 2011;11:13
13ISD Scotland. Acute Surgical Speciality Costs. In: [25 November 2015]
15Pasquale, K, Wiatrak, B, Woolley, A, Lewis, L.Microdebrider versus CO2 laser removal of recurrent respiratory papillomas: a prospective analysis. Laryngoscope 2003;113:139–43
16Cohen, SM, Kim, J, Roy, N, Asche, C, Courey, M.Direct health care costs of laryngeal diseases and disorders. Laryngoscope 2012;122:1582–8
17Blomberg, M, Dehlendorff, C, Munk, C, Kjaer, SK.Strongly decreased risk of genital warts after vaccination against human papillomavirus: nationwide follow-up of vaccinated and unvaccinated girls in Denmark. Clin Infect Dis 2013;57:929–34
18Langley, PC, White, DJ, Drake, SM.The costs of treating external genital warts in England and Wales: a treatment pattern analysis. Int J STD AIDS 2004;15:501–8


Economic impact of recurrent respiratory papillomas in a UK adult population

  • A Harrison (a1), J Montgomery (a2) and F B Macgregor (a3)


Altmetric attention score

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed